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Abstract
Background: Recent epidemiologic data suggest that the prevalence of macrolide resistant Mycoplasma
pneumoniae (MR-M. pneumoniae) is increasing rapidly worldwide. This study assessed the present status of
M. pneumoniae infection in Japan and clinical end-points to distinguish children with MR-M. pneumoniae.
Methods: During an outbreak of M. pneumoniae infections in Fukuoka, Japan in 2010–11, a total of 105 children
with clinically suspected M. pneumoniae infection were enrolled. M. pneumoniae was analyzed for macrolide
resistance in domain V of the 23S rRNA gene. Sixty -five patients with PCR positive for M. pneumoniae were
analyzed with regard to clinical symptoms, efficacy of several antimicrobial agents and several laboratory data.
Results: Causative pathogens were detected in 81.0% (85 of 105) and M. pneumoniae was identified 61.9%
(65 of 105). The resistance rate of M. pneumoniae was 89.2% (58 of 65) in this general pediatric outpatient setting.
Patients infected with MR-M. pneumoniae showed longer times to resolution of fever and required frequent
changes of the initially prescribed macrolide to another antimicrobial agent. We observed three different genotypes
of M. pneumoniae including the rarely reported A2063T mutation (A2063G: 31 strains, A2063T: 27 strains, no
mutation: 7 strains). Drug susceptibility testing showed different antimicrobial susceptibility profiles for each
genotype. Serum IFN-gamma, IL-6 and IP-10 levels were higher in patients with MR-genotypes than in those
infected with no-mutation strains (p < 0.001).
Conclusions: Macrolide resistance is more common than previously thought and a small epidemic of rarely
reported A2063T mutation was observed in Fukuoka, Japan. Furthermore our results reveal the possibility that levels
of certain inflammatory cytokines may be a candidate to predict MR-M.pneumoniae infection.
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Background
Mycoplasma pneumoniae (M. pneumoniae) is a common
bacterial cause of upper and lower respiratory tract infec-
tions in children and adolescents. Recent advances in anti-
microbial agents, including macrolide antibiotics [1],
tetracyclines and fluoroquinolones, have enabled its treat-
ment on an outpatient basis for most children with
community-acquired pneumonia. Since the time when
macrolide resistant (MR) M. pneumoniae was first isolated
from a pediatric patient in 2000 [2], the drug resistance
trend has been documented all over the world [3-10], es-
pecially in children. Extremely high rates of macrolide re-
sistance have been reported mainly in Asian countries
[3,4]. According to the continuous surveillance in Japan,
the frequency of MR-M. pneumoniae cases has increased
year by year, and nowadays >80% of M. pneumoniae iso-
lates were shown to be macrolide resistant [4]. However,
most of these reports included the data in secondary or
tertiary care facilities; thus very little information is cur-
rently available on the prevalence of MR-M. pneumoniae
infection, especially in outpatient settings. Macrolide-
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resistant genotypes can be defined by the detection of spe-
cific point mutations in the domain V of the single-operon
derived 23S rRNA gene of M. pneumoniae. While most
frequent mutations that induce high levels of macrolide-
resistance included an A-to-G transition at position 2063
or 2064 [11,12], recent epidemiologic studies have sug-
gested that distribution of MR-M. pneumoniae genotypes
has been changing [4,13]. The primary objective of our
study was to clarify the present status of MR-M. pneumo-
niae. For the present, it is difficult to make an early identi-
fication of which children being infected by MR-M.
pneumoniae. Thus, secondly, we evaluated children with
M. pneumoniae infections with regard to clinical symp-
toms, efficacy of several antimicrobial agents and several




Between September 2010 and December 2011, a total of
105 patients with clinically suspected M. pneumoniae in-
fection were recruited from Matsuda Children’s Clinic
(Onojo-city, Fukuoka Prefecture) after informed consent
was obtained from both the children and their parents.
Nasopharyngeal swab specimens and blood samples were
obtained from all patients at the time of enrollment, and
the throat swabs were sent to the Laboratory of Virology,
Fukuoka Institute of Health and Environmental Sciences.
Laboratory-confirmed M. pneumoniae infection was
defined as detection of M. pneumoniae DNA from the
throat swab by PCR methods. Multiplex PCR was carried
out as described previously [14,15]. M. pneumoniae, rhino-
viruses (RV), respiratory syncytial virus (RSV), coronaviruses,
human metapneumovirus (HMPV), human bocavirus, in-
fluenza A, and B viruses, adenovirus and parainfluenza
virus (PIV 1–4). Ultimately, data on 65 children (33 girls,
32 boys; mean age 6.1 years) with positive for M. pneumo-
niae were analyzed. This study was approved by the Ethical
Committee of Kurume University School of Medicine and
the National Research Institute for Child Health and
Development.
Measurement of biologic markers
To evaluate the disease activity of M. pneumoniae infec-
tion, we performed general blood tests, including white
blood cell (WBC) counts, C-reactive protein (CRP),
erythrocyte sedimentation rate (ESR) at the time of
throat swab collection. Serum concentrations of chemo-
kines and cytokines were measured using Luminex
xMAP technology (Milliplex MAP kits; Millipore,
Billerica, MA, USA) according to the manufacturer’s in-
structions. The detection limits are 2.0, 12.5, 1.13, 8.0,
and 1.21 pg/mL for IL-8, IL-18, IFN- gamma, IP-10 and
IL-6, respectively.
Measurement of clinical efficacy
Clinical records of the patients with M. pneumoniae in-
fection were examined retrospectively. Precise quantita-
tive data such as total duration of fever and the usage of
antibiotics which were obtained from the clinical charts
and the clinical courses of patients infected by each of
the three different genotypes (A2063G, A2063T, and no
mutation) were compared. A febrile day was defined as a
day during which the body temperature exceeded 37.5°C.
As an indicator of the severity of mycoplasma infection,
the number of patients requiring hospitalization was also
assessed. The chemotherapeutical agent was often chan-
ged from a macrolide to minocycline (MIN) or tosu-
floxacin (TFX) according to clinical conditions such as
persistent fever and cough as well as chest X-ray findings.
The attending physician (K. Matsuda) had no information
about the susceptibility to M. pneumoniae at the time of
clinical decision-making.
PCR amplification and sequencing
The mutations associated with resistance to macrolides
were detected by sequencing the targeted domain V re-
gion of the 23S rRNA gene as described by Matsuoka
et al. (11) using the following primers for domain V of
23S rRNA (Forward:5′-GCAGTGAAGAAGAACGAGG
GG-3′, Reverse:5′-GTCCTCGCTTCGGTCCTCTCG-
3′) which were synthesized as reported by Lucier et al.
[16]. The sequences were aligned using the ClustalW
option within the software Molecular Evolutionary Gen-
etics Analysis (MEGA) 4.0.2 (http://www.megasoftware.
net/) and compared to the registered sequence of M.
pneumoniae M129 (accession No. ×68422).
Minimal inhibitory concentration determination
Minimal inhibitory concentrations (MICs) of antibiotics
were determined by a broth microdilution method based
on the National Committee for Clinical Laboratory Stan-
dards (Clinical and Laboratory Standards Institute) as
described elsewhere [2,11].
The following antibiotics were tested: erythromycin
(ERY), clarithromycin (CLR), azithromycin (AZM), josa-
mycin (JOS), rokitamycin (RKI), clindamycin (CLI),
tetracycline (TET), MIN, levofloxacin (LVX), ciprofloxa-
cin (CPX), TFX, sparfloxacin (SPX) and gatifloxacin
(GFX). Briefly, serial twofold dilutions of antibiotics were
prepared in the Mycoplasma broth base inoculated by
104 to 105 CFU/ml of M. pneumoniae in 96-well micro-
plates and incubated at 37°C. The MIC was determined
as the lowest concentration of antimicrobial agent at
which the color of the control medium changed. The de-
gree of resistance was evaluated according to the Japanese
standard (</= 4 μg/mL; susceptible, 8 μg/mL; intermedi-
ate, > /= 16 μg/mL; resistant, for ERY, CLR, AZM, JOS,
RKI, CLI) [17].
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Statistical analysis
Statistical analysis was performed using the computing
environment R (R Development Core Team, 2012). The
data in Table 1 are presented as medians (1st and 3rd
quartiles). The Kruskal-Wallis test or Fisher’s exact test
was used for multiclass comparison (A2063G, A2063T,
no mutation). If the results were significant, then the
Wilcoxon rank-sum test was used for pairwise compari-
sons (A2063G vs no mutation, A2063T vs no mutation,
and A2063G vs A2063T, respectively). P-values less than
0.05 were regarded as statistically significant.
Results
Subject characteristics
During this study period, a total of 105 children were en-
rolled in this study. The causative pathogens identified
were; M.pneumoniae (n = 65, 61.9%), RV (n = 6, 5.7%),
HMPV (n = 6, 5.7%), influenza B virus (n = 5, 4.7%), PIV
(n = 4, 3.8%), RSV (n = 1, 1%), adeno virus (n = 1, 1%).
Mixed viral infections were found in 3 (2.9%) cases.
Sixty -five patients (61.9%) with PCR positive for M.
pneumoniae were analyzed. The patients’ clinical charac-
teristics are shown in Table 1. All patients were outpa-
tients at the time of onset and had no severe underlying
illnesses, nor a history of receiving systemic corticoste-
roids prior to enrollment. Macrolide-resistant mutations
in domain V of the 23S rRNA gene were detected in
89.2% (58/65) of the children with M. pneumoniae infec-
tion, while the remaining 7 (10.8%) were found to harbor
no mutation known to be associated with resistance in
that region. Thirty-one of the 58 macrolide-resistance
mutations (53.5%) showed the A2063G transition; the
remaining 27 (46.5%) showed the A2063T transversion in
domain V of the 23S rRNA gene. The three groups
(A2063G, A2063T, no mutation) did not differ signifi-
cantly in age, gender distribution or number of days be-
tween the onset of initial symptoms and the examination
performed (Table 1).
Patient diagnosis and medication
Detailed information concerning the antimicrobial agents
prescribed at the clinic is shown in Table 1. Briefly, fifty-
three of 65 (81.5%) patients were initially treated with the
14-membered-ring macrolide CLR or the 15-membered-
ring macrolide AZM. In a total of 47 patients (72.3%)
these antibiotics were eventually changed to MIN or TFX
because of persistent fever, cough, and worsening of chest
X-ray findings. A significant difference was observed in
the number of patients needing to change to another
antimicrobial agent among the three groups (p = 0.001).
Specifically, patients with the A2063G transition (90.3%)
were more likely to have had the initially prescribed
macrolide changed to another antimicrobial agent other
than a macrolide in comparison not only to macrolide-
sensitive patients (28.6%, p = 0.001) but also to those with
A2063T transversion (63.0%, p = 0.02). Fever disappeared
dramatically within 48 hr after changing to other drugs
such as MIN or TFX in all patients whose clinical find-
ings had failed to improve or whose chest radiographic
findings had worsened during the initial treatment. In
two patients, symptoms resolved spontaneously without
any antibiotics (one with no mutation and the other with
A2063T). With regard to the timing of sample collection,
44 of the 65 patients with M. pneumoniae had already
been treated with antimicrobial agents before nasopha-
ryngeal specimens were collected. There were no statisti-
cally significant differences in the incidence of macrolide
resistance as to whether sample was collected before or
after antimicrobial agents administration (in 17 of 21
(81.0%) collected before administration, and in 41 of 44
(93.2%) collected after administration, p = 0.25).
Comparison of the clinical courses
The total number of febrile days was significantly greater in
patients infected with either of the macrolide-resistance ge-
notypes than in those infected with the no-mutation strains
(A2063G: 7.0 days, A2063T: 7.0 days, no mutation: 5.0 days;
comparison of A2063G vs no mutation: p = 0.03, A2063T
vs no mutation: p = 0.01, and A2063G vs A2063T: not sig-
nificant). Two patients (one with A2063G and the other
with A2063T) required hospitalization because of the pro-
gression to dyspnea and the development of a secondary
bacterial infection (Table 1).
Measurement of biologic indicators of inflammation
No significant differences were observed among each
genotype group with regard to the results of any acute
phase general infection markers (WBC, CRP, ESR).
Whereas serum IL-8 and IL-18 levels were not different
among the three groups, significant differences were ob-
served in the levels of some serum inflammatory cytokines
among the three groups. Serum IFN- gamma, IL-6 and
IP-10 levels were significantly higher in patients infected
by the macrolide-resistance genotypes than in those
infected by the no-mutation strains (comparison of
A2063G vs. no mutation: p < 0.001, A2063T vs no muta-
tion: p < 0.001 and A2063G vs A2063T: not significant,
Table 1).
Antimicrobial susceptibility
MICs could be measured exclusively for 15 clinical
strains obtained between November and December 2011
(A2063G; 11 strains, A2063T; 4 strains, Table 2) for the
reason of performed facilities’ difficulties. Both the
A2063G mutation and the A2063T mutation yielded a
high degree of resistance to ERY and CLR (MIC range,
64 to >256 μg/mL), though both mutated genotypes ex-
hibited no elevation of MICs for MIN and TFX.
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Although the 11 strains with the A2063G mutation ex-
hibited variable resistance (MICs 4–64 μg/mL) to the
15-membered macrolide AZM, all 4 strains with the
A2063T mutation were susceptible to AZM (MIC
0.25 μg/mL). In addition, we performed the multiple-
locus variable-number tandem-repeat analysis (MLVA)
for these 15 strains according to the previously described
method (18) and found 6 different MLVA types (4 types







p* P1 P2 P3
Age (years) 7.0 (4.0 – 9.5) 7.0 (4.5 – 8.0) 4.0 (3.0 – 7.5) ns
Gender (M/F) 14 / 17 15 / 12 3 / 4 ns
Day exam performed 4 (4 – 6) 5 (4 – 5) 5 ( 4 – 5) ns
WBC 5850 6200 6350 ns
(/μl) (5050–6250) (5650–7075) (5375–6800)
CRP 1.35 0.90 1.75 ns
(mg/dL) (0.90 - 1.95) (0.53 -2.48) (0.63 - 4.08)
ESR 29.0 30.0 34.5 ns
(mm/hr) (22.75 - 40.50) (22.0 - 44.25) (25.25 - 52.0)
IL-8 14.2 20.1 29.88 ns
(pg/mL) (9.1 - 34.3) (15.2- 26.0) (18.4 - 84.8)
IL-18 457.0 477.7 533.8 ns
(pg/mL) (410.2 - 571.6) (362.5 - 564.2) (420.9 - 629.8)
IFN-γ 15.9 18.1 11.5 < 0.001 < 0.001 < 0.001 ns
(pg/mL) (10.4 – 27.2) (4.7 – 38.6) (8.8 – 12.7)
IP-10 1019 931 643.5 < 0.001 < 0.001 < 0.001 ns
(pg/mL) (794–1378) (659 – 1519.5) (550.7 – 873.0)
IL-6 6.57 7.79 5.86 < 0.001 < 0.001 < 0.001 ns
(pg/mL) (2.77 – 13.73) (3.34 – 16.38) (3.16 – 11.58)
Initial antibiotics used
none 0 1 1
β-lactam 3 3 0
14-macrolide 13 11 3
15-macrolide 13 10 3
Quinolones 0 1 0
Minocycline 2 0 0
Secondary antibiotics used
14-macrolide 1 0 0
15-macrolide 2 7 0
Quinolones 2 1 0
Minocycline 26 16 2
Total duration of fever (days) 7.0 (5.0 – 8.0) 7.0 (5.5 – 8.0) 5.0 (5.0 – 5.5) p* = 0.04 P1 = 0.03 P2 = 0.01 P3 = ns
Number of patients for whom
non-macrolide antibiotics were
used as secondary antibiotics
28 (90.3%) 17 (63.0%) 2 (28.6%) p* = 0.001 P1 = 0.001 P2 = ns P3 = 0.02
Number of patients requiring hospitalization 1 (3.2%) 1 (3.7%) 0 (0%) ns
Data represent medians (1st quantile - 3rd quantile). The Kruskal-Wallis test and Fisher exact test were used to compare the three groups. Wilcoxon test was used
to assess pairwise difference.
p*: comparison of A2063G, A2063T and no mutation.
P1, P2, P3: comparison of A2063G vs. no mutation, A2063T vs. no mutation, and A2063G vs. A2063T, respectively.
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for the 11 strains of A2063G and other 2 types for the 4
strains of A2063T, data not shown). There was no obvi-
ous link between the MLVA type and the patient’s age
and residential area, or resistance to macrolides.
Discussion
In the present study, we have clarified 89.2% of pediatric
M. pneumoniae infections were caused by either of two
macrolide-resistant genotypes of M. pneumoniae. The
incidence of MR-M. pneumoniae in this general
pediatric outpatient setting was nearly as high as those
described in continuous surveillance in Japan [4].
Thirty-one of the 58 MR-M. pneumoniae strains (53.5%)
harbored an A-to-G transition mutation at position 2063
in the 23S rRNA genes, which was consistent with previ-
ously reported findings [18] that the A2063G transition
was the most frequent mutation. A striking finding in
our present work is that the remaining 27 samples
(46.5%) showed an A-to-T transversion at position 2063
in the 23S rRNA genes. The A2063T mutation was first
reported in China during 2008–2009 [3,19] but has been
rarely reported thereafter. However, recent reports from
Japan have revealed that the A2063T transversion have
been increasing [4,13]. A community outbreak of
A2063T transversion was reported recently in Yamagata,
Japan, in 2009 [13]. In this point, the resistant strains in
our study were polyclonal in origin, which is consistent
with the previous report [20]. Although the precise
mechanisms of outbreak of the A2063T transversion
mutation are not yet known, in general, transversion
mutations that change the chemical structure dramatic-
ally are thought to affect bacterial growth more severely
and in consequence to be less common than transition
mutations. For example, an in-vitro study revealed that
the mutation rate of A-to-T transversion is less than
one-tenth that of A-to-G transition in E. coli cells, coin-
ciding with the spontaneous misinsertion rate of its
DNA polymerase III [21].
Another important finding in our study is the profile
of serum cytokines and chemokines. It is true that gene
amplification methods such as real-time PCR [7] and py-
rosequencing [22] must be a best way to detect resist-
ance, however, these methods are confined to very few
specialized laboratories in Japan. For reason of that, we
expect some additional information on pathogenesis of
mycoplasmal infection through measurement of cyto-
kines and chemokines. Higher levels in serum were
found for some inflammatory cytokines such as IFN-
gamma, IP-10 and IL-6 in patients infected by the
macrolide-resistant strains than in those infected by the
strains with no-mutation, while no difference was ob-
served in the levels of IL-8 and IL-18 between the two
groups. It has been thought IL18 and IL-8 play a pivotal
role in the pathogenesis of M. pneumonia infection ac-
cording to the disease severity [23,24]. There are several
explanations for this discrepancy. First, disease severity
was not so high in our patients infected with macrolide-
resistant strains. Indeed we did not experience apparent
treatment failure or serious illness. These findings were
consistent with previous reports which showed that drug
resistance in M. pneumoniae does not always lead to se-
vere clinical manifestations [25,26]. Second, the timing
of blood sampling might alter the levels of these cyto-
kines as reported by Narita et al. [27], since we only per-
formed blood sampling at the time of enrollment.
On the other hand, the higher levels of IFN- gamma, IP-
10 and IL-6 in the patients with MR-M. pneumoniae in-
fection might reflect, as a non-specific inflammatory
marker, the prolonged low degree of inflammation which
is represented by slightly longer duration of fever due to
the drug resistance. Our results imply the possibility that
in addition to the lower clinical efficacy of macrolide
treatment, measurement of levels of certain inflamma-
tory cytokines may be a strong candidate that allows the
clinicians to suspect MR-M. pneumoniae infection.
Strains with the A2063G transition were highly resistant
to 14- and 15-membered-ring macrolides as previously
described [11,25] and the patients infected by the strains
with this mutation were more likely to have had the ini-
tially prescribed macrolide changed to a non-macrolide
Table 2 MICs of selected antimicrobial agents for 15 strains of M. pneumoniae isolated from clinical samples
Point mutation No of strains ERY CLR AZM JOS RKI CLI TET MIN LVX CPX TFX SPX GFX
A2063G 3 256 > 256 16 16 1 256 1 1 1 1 0.25 0.0625 0.0625
A2063G 2 256 256 16 16 1 256 1 1 1 1 0.25 0.0625 0.0625
A2063G 1 > 256 256 64 16 1 256 1 1 1 1 0.25 0.0625 0.0625
A2063G 1 256 256 16 16 1 128 1 1 1 1 0.25 0.0625 0.0625
A2063G 1 256 256 16 4 1 256 1 1 1 1 0.25 0.0625 0.0625
A2063G 1 256 > 256 8 8 1 256 1 0.25 1 1 0.25 0.0625 0.0625
A2063G 1 256 256 4 4 1 16 1 1 1 1 0.25 0.0625 0.0625
A2063G 1 64 64 4 16 0.5 16 0.5 0.5 1 1 0.25 0.0625 0.0625
A2063T 4 64 64 0.25 16 4 256 1 1 1 1 0.25 0.0625 0.0625
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antimicrobial agent when compared with the patients in-
fected not only by macrolide-sensitive strains (p = 0.001)
but also by A2063T transversion strains (p = 0.02). As
shown by the susceptibility testing, all four strains with
the A2063T mutation showed lower MICs for AZM
(0.25 μg/mL), and actually, the eight patients with
A2063T mutation who were treated with AZM showed
complete resolution of clinical symptoms. Thus our data
showed that the in-vitro susceptibility directly predicts the
clinical efficacy as previously reported [25,26,28]. The rea-
son why AZM is effective in patients with an A2063T
transversion is unclear. One plausible explanation is a dif-
ference in chemical structures. That is, while the binding
of 14-membered-ring macrolides to A2063 is affected
both by the G transition and by the T transversion, the
binding of 15-membered-ring macrolides to A2063 is not
affected by T transversion. Nevertheless, since the
A2063T transversion mutation must be related to more
profound damage to growth efficiency, the reason re-
mains unknown why so many strains with the rarely re-
ported A2063T mutation, a total of 27, were isolated in
this study (in the Fukuoka area). Interestingly, the
A2063T mutation slightly but significantly raises the
MICs for RKI (4 μg/mL), in contrast to the fact that
the strains with the A2063G mutation can be considered
susceptible to this macrolide (1 μg/mL). This suggests
that A2063G transposition does not affect the binding of
RKI to the domain V while A2063T transversion affects
the binding to some degree.
The limitations of the present study is that the study
was a single-center study conducted over one year; ac-
cordingly, the sample number was limited, and the stat-
istical power may therefore have been insufficient to
elucidate the linkage between drug susceptibility and
genotype of M. pneumonia. Further studies including
larger sample sizes to investigate the predictive factors
of macrolide-resistance are necessary.
Conclusions
Practical implications of our present study are that the
prevalence of MR-M. pneumoniae is increasing more
rapidly than we thought, even in general outpatient set-
tings and drug susceptibility may be different for each
genotype. Moreover, our results reveal the possibility that
levels of certain inflammatory cytokines such as IL-6, IP-
10 and IFN- gamma may be a candidate to predict MR-
M. pneumoniae infection at the early stage of infection.
In view of these findings, treatment should be tailored to
each patient or at least taking into account which patient
is infected by the particular genotype, and the treatment
strategies must be optimized for each genotype.
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